{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:55:51Z","timestamp":1793850951191,"version":"4.6.1"},"reference-count":124,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-alcoholic fatty liver disease (NAFLD) has become a public health issue worldwide. Dietary polyphenols are naturally occurring plant active ingredients and are widely employed in the treatment of NAFLD. However, the therapeutic effect is still controversial. In this study, a network meta-analysis (NMA) was performed to appraise the effects of various polyphenols on metabolic indices of NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, the Cochrane Library, and Web of Science were retrieved for English studies on dietary polyphenols in the treatment of NAFLD. Outcome measures were extracted from the included studies and compared using a Bayesian NMA model, encompassing body mass index (BMI), alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and necrosis factor alpha (TNF-\u03b1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 54 randomized controlled trials (RCTs) were included in this study, including 3,132 participants. It involved 13 single (or combined) dietary polyphenols. Naringenin could reduce serum TC (surface under the cumulative ranking curve: 94.59%) and TG (99.00%) in NAFLD patients. Catechin could decrease BMI (77.74%) and serum ALT (94.21%), AST (93.56%), TC (92.26%), and increase HDL-C (93.72%). Dihydromyricetin (DHM) was effective in reducing serum LDL-C (73.22%), and quercetin decreased serum TNF-\u03b1 (99.47%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Catechin may be the most appropriate dietary polyphenol supplement for NAFLD. Future studies should incorporate more RCTs to further validate the efficacy of dietary polyphenols (like DHM and quercetin), which are limited in sample sizes, in treating NAFLD. On the other hand, it is essential to investigate improvements in the bioavailability of these dietary polyphenols and to clarify their safety profiles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2025.1582861","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T08:34:11Z","timestamp":1746779651000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy of dietary polyphenol supplement in patients with non-alcoholic fatty liver disease: a network meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiao-cui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity\u2014a longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ejca.2022.06.051","article-title":"Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"173","author":"Thomas","year":"2022","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1007\/s10620-017-4684-x","article-title":"Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes","volume":"62","author":"Cholankeril","year":"2017","journal-title":"Dig Dis Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1016\/j.apsb.2022.08.022","article-title":"New opportunities and challenges of natural products research: when target identification meets single-cell multiomics","volume":"12","author":"Zhu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3390\/nu13020494","article-title":"Dietary polyphenols and non-alcoholic fatty liver disease","volume":"13","author":"Abenavoli","year":"2021","journal-title":"Nutrients"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"949746","DOI":"10.3389\/fimmu.2022.949746","article-title":"Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-1-0716-1566-9_12","article-title":"Network meta-analysis","volume":"2345","author":"Watt","year":"2022","journal-title":"Methods Mol Biol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/sim.6381","article-title":"Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis","volume":"34","author":"Turner","year":"2015","journal-title":"Stat Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/1469-0691.12494","article-title":"The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses","volume":"20","author":"Melsen","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1002\/sim.4172","article-title":"Multivariate meta-analysis: potential and promise","volume":"30","author":"Jackson","year":"2011","journal-title":"Stat Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41430-018-0382-9","article-title":"The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease","volume":"73","author":"Saadati","year":"2019","journal-title":"Eur J Clin Nutr"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.22377\/ijgp.v17i03.3472","article-title":"Evaluation of the safety and efficacy of CurcuVail\u00ae in patients with non-alcoholic fatty liver disease\u2014a prospective randomized, double blind, placebo controlled, parallel group study","volume":"17","author":"Patel","year":"2023","journal-title":"Int J Green Pharm"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"15989","DOI":"10.1002\/jcb.28877","article-title":"Curcuminoids plus piperine improve nonalcoholic fatty liver disease: a clinical trial","volume":"120","author":"Panahi","year":"2019","journal-title":"J Cell Biochem"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"102322","DOI":"10.1016\/j.ctim.2020.102322","article-title":"Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: a randomized controlled trial","volume":"49","author":"Saberi-Karimian","year":"2020","journal-title":"Complement Ther Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-3-030-73234-9_2","article-title":"Curcumin and piperine combination for the treatment of patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled trial","volume":"1328","author":"Mirhafez","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/ptr.7764","article-title":"Efficacy of curcumin plus piperine co-supplementation in moderate-to-high hepatic steatosis: a double-blind, randomized, placebo-controlled clinical trial","volume":"37","author":"Sharifi","year":"2023","journal-title":"Phytother Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s41110-023-00236-5","article-title":"Benefits of Pilates training and nano-curcumin supplementation for overweight and obese females with NAFLD: a pilot study","volume":"48","author":"Rezaei","year":"2023","journal-title":"Forum Nutr"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12986-019-0331-1","article-title":"Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial","volume":"16","author":"Jazayeri-Tehrani","year":"2019","journal-title":"Nutr Metab"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jbmt.2020.02.021","article-title":"Effects of non-linear resistance training and curcumin supplementation on the liver biochemical markers levels and structure in older women with non-alcoholic fatty liver disease","volume":"24","author":"Kelardeh","year":"2020","journal-title":"J Bodyw Mov Ther"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/FJC.0000000000000406","article-title":"Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"68","author":"Panahi","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1055\/s-0043-100019","article-title":"Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease: a randomized controlled trial","volume":"67","author":"Panahi","year":"2017","journal-title":"Drug Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-3-030-64872-5_3","article-title":"The effect of curcumin phytosome on the treatment of patients with non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled trial","volume":"1308","author":"Mirhafez","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"105202","DOI":"10.1016\/j.jff.2022.105202","article-title":"Evaluation of the effect of phytosomal curcuminoids on oxidative stress and inflammatory markers in NAFLD: a randomized double-blind placebo-controlled trial","volume":"96","author":"Hosseinian","year":"2022","journal-title":"J Funct Foods"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1163950","DOI":"10.3389\/fnut.2023.1163950","article-title":"The effect of curcumin on anthropometric indices, blood pressure, lipid profiles, fasting blood glucose, liver enzymes, fibrosis, and steatosis in non-alcoholic fatty livers","volume":"10","author":"Safari","year":"2023","journal-title":"Front Nutr"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/07315724.2016.1267597","article-title":"Turmeric supplementation improves serum glucose indices and leptin levels in patients with nonalcoholic fatty liver diseases","volume":"36","author":"Navekar","year":"2017","journal-title":"J Am Coll Nutr"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1024\/0300-9831\/a000568","article-title":"Turmeric and chicory seed have beneficial effects on obesity markers and lipid profile in non-alcoholic fatty liver disease (NAFLD)","volume":"89","author":"Ghaffari","year":"2019","journal-title":"Int J Vitam Nutr Res"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13098-021-00731-7","article-title":"The effect of turmeric on lipid profile, malondialdehyde, liver echogenicity and enzymes among patients with nonalcoholic fatty liver disease: a randomized double blind clinical trial","volume":"13","author":"Jarhahzadeh","year":"2021","journal-title":"Diabetol Metab Syndr"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3746\/pnf.2022.27.1.37","article-title":"Effect of turmeric supplementation on blood pressure and serum levels of Sirtuin 1 and adiponectin in patients with nonalcoholic fatty liver disease: a double-blind, randomized, placebo-controlled trial","volume":"27","author":"Kalhori","year":"2022","journal-title":"Prev Nutr Food Sci"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.cgh.2014.02.024","article-title":"Resveratrol does not benefit patients with nonalcoholic fatty liver disease","volume":"12","author":"Chachay","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.dld.2014.11.015","article-title":"Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial","volume":"47","author":"Chen","year":"2015","journal-title":"Dig Liver Dis"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3109\/00365521.2015.1107620","article-title":"Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease","volume":"51","author":"Heeb\u00f8ll","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1024\/0300-9831\/a000528","article-title":"No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease","volume":"90","author":"Farzin","year":"2020","journal-title":"Int J Vitam Nutr Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.nutres.2014.09.005","article-title":"Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease","volume":"34","author":"Faghihzadeh","year":"2014","journal-title":"Nutr Res"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1017\/S0007114515002433","article-title":"The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study","volume":"114","author":"Faghihzadeh","year":"2015","journal-title":"Br J Nutr"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/07315724.2017.1392264","article-title":"Comparison of calorie-restricted diet and resveratrol supplementation on anthropometric indices, metabolic parameters, and serum Sirtuin-1 levels in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial","volume":"37","author":"Asghari","year":"2018","journal-title":"J Am Coll Nutr"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"307","DOI":"10.15171\/apb.2018.036","article-title":"Effects of pharmacologic dose of resveratrol supplementation on oxidative\/antioxidative status biomarkers in nonalcoholic fatty liver disease patients: a randomized, double-blind, placebo-controlled trial","volume":"8","author":"Asghari","year":"2018","journal-title":"Adv Pharm Bull"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.1097\/MD.0000000000000758","article-title":"A CONSORT-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease","volume":"94","author":"Zhang","year":"2015","journal-title":"Medicine"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/ptr.6826","article-title":"Effect of sour tea supplementation on liver enzymes, lipid profile, blood pressure, and antioxidant status in patients with non-alcoholic fatty liver disease: a double-blind randomized controlled clinical trial","volume":"35","author":"Izadi","year":"2021","journal-title":"Phytother Res"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.1002\/ptr.7199","article-title":"The effect of (Cornus mas L.) fruit extract on liver function among patients with nonalcoholic fatty liver: a double-blind randomized clinical trial","volume":"35","author":"Sangsefidi","year":"2021","journal-title":"Phytother Res"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5812\/hepatmon-132309","article-title":"Effectiveness of grape seed extract in patients with nonalcoholic fatty liver: a randomized double-blind clinical study","volume":"22","author":"Mojiri-Forushani","year":"2022","journal-title":"Hepat Mon"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clnesp.2023.04.018","article-title":"Effect of Cornus mas L. fruit extract on blood pressure, anthropometric and body composition indices in patients with non-alcoholic fatty liver disease: a double-blind randomized controlled trial","volume":"56","author":"Yarhosseini","year":"2023","journal-title":"Clin Nutr ESPEN"},{"key":"ref54","first-page":"265","article-title":"A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease","volume":"9","author":"Hashemi","year":"2009","journal-title":"Hepat Mon"},{"key":"ref55","first-page":"181","article-title":"Effects of silymarin on reducing liver aminotransferases in patients with nonalcoholic fatty liver diseases","volume":"18","author":"Masoodi","year":"2013","journal-title":"GOVARESH"},{"key":"ref56","first-page":"9","article-title":"Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial","volume":"5","author":"Solhi","year":"2014","journal-title":"Caspian J Intern Med"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.cgh.2017.04.016","article-title":"A randomized trial of Silymarin for the treatment of nonalcoholic steatohepatitis","volume":"15","author":"Wah Kheong","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/MEG.0000000000001369","article-title":"Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial","volume":"31","author":"Anushiravani","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3892\/ijmm.2013.1503","article-title":"Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: a double-blind placebo-controlled study","volume":"32","author":"Sakata","year":"2013","journal-title":"Int J Mol Med"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4103\/2008-7802.173051","article-title":"The effect of green tea extract supplementation on liver enzymes in patients with nonalcoholic fatty liver disease","volume":"7","author":"Pezeshki","year":"2016","journal-title":"Int J Prev Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"931","DOI":"10.12669\/pjms.334.12571","article-title":"Therapeutic benefits of green tea extract on various parameters in non-alcoholic fatty liver disease patients","volume":"33","author":"Hussain","year":"2017","journal-title":"Pak J Med Sci"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5812\/hepatmon.14993","article-title":"Green tea in non-alcoholic fatty liver disease: a double blind randomized clinical trial","volume":"17","author":"Tabatabaee","year":"2017","journal-title":"Hepat Mon"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e12299","DOI":"10.5812\/hepatmon.45609","article-title":"Effects of green coffee bean extract supplementation on patients with non-alcoholic fatty liver disease: a randomized clinical trial","volume":"63","author":"Shahmohammadi","year":"2017","journal-title":"Hepat Mon"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"180","DOI":"10.23751\/pn.v21i2-S.7267","article-title":"Effects of green coffee extract supplementation on blood pressure and antioxidants status in patients with non-alcoholic fatty liver disease","volume":"21","author":"Hosseinabadi","year":"2019","journal-title":"Prog Nutr"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"102290","DOI":"10.1016\/j.ctim.2019.102290","article-title":"Effect of green coffee extract supplementation on serum adiponectin concentration and lipid profile in patients with non-alcoholic fatty liver disease: a randomized, controlled trial","volume":"49","author":"Hosseinabadi","year":"2020","journal-title":"Complement Ther Med"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"100340","DOI":"10.1016\/j.hermed.2020.100340","article-title":"Effects of green coffee extract supplementation on glycemic indexes, leptin, and obesity values in patients with non-alcoholic fatty liver disease","volume":"22","author":"Hosseinabadi","year":"2020","journal-title":"J Herb Med"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1002\/ptr.7249","article-title":"The effect of pomegranate extract on anthropometric indices, serum lipids, glycemic indicators, and blood pressure in patients with nonalcoholic fatty liver disease: a randomized double-blind clinical trial","volume":"35","author":"Goodarzi","year":"2021","journal-title":"Phytother Res"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12937-023-00869-2","article-title":"Pomegranate (Punica granatum L.) peel extract ameliorates metabolic syndrome risk factors in patients with non-alcoholic fatty liver disease: a randomized double-blind clinical trial","volume":"22","author":"Barghchi","year":"2023","journal-title":"Nutr J"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.clnu.2017.05.028","article-title":"Genistein supplementation improves insulin resistance and inflammatory state in non-alcoholic fatty liver patients: a randomized, controlled trial","volume":"37","author":"Amanat","year":"2018","journal-title":"Clin Nutr"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1038\/s41598-024-55747-6","article-title":"The effect of soy isoflavones on non-alcoholic fatty liver disease and the level of fibroblast growth factor-21 and fetuin A","volume":"14","author":"Neshatbini Tehrani","year":"2024","journal-title":"Sci Rep"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"e14852","DOI":"10.1111\/ijcp.14852","article-title":"Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight\/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial","volume":"75","author":"Namkhah","year":"2021","journal-title":"Int J Clin Pract"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/MEG.0000000000002323","article-title":"Effects of naringenin supplementation on cardiovascular risk factors in overweight\/obese patients with nonalcoholic fatty liver disease: a pilot double-blind, placebo-controlled, randomized clinical trial","volume":"34","author":"Naeini","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2015.05.009","article-title":"Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: a randomized controlled trial","volume":"99","author":"Chen","year":"2015","journal-title":"Pharmacol Res"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1002\/ptr.6406","article-title":"Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled, double-blind clinical trial","volume":"33","author":"Cheraghpour","year":"2019","journal-title":"Phytother Res"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1108\/NFS-10-2019-0321","article-title":"Quercetin supplementation in non-alcoholic fatty liver disease a randomized, double-blind, placebo-controlled clinical trial","volume":"50","author":"Hosseinikia","year":"2020","journal-title":"Nutr Food Sci"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"361","DOI":"10.31989\/ffhd.v12i7.958","article-title":"A blend of Sphaeranthus indicus flower head and Terminalia chebula fruit extracts reduces fatty liver and improves liver function in non-alcoholic, overweight adults","volume":"12","author":"Rajendra","year":"2022","journal-title":"Funct Foods Health D"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1002\/ptr.8182","article-title":"Effects of different natural products in patients with non-alcoholic fatty liver disease-a network meta-analysis of randomized controlled trials","volume":"38","author":"Liu","year":"2024","journal-title":"Phytother Res"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"Le","year":"2023","journal-title":"J Hepatol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3390\/molecules24030528","article-title":"Catechin in human health and disease","volume":"24","author":"Isemura","year":"2019","journal-title":"Molecules"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/mnfr.201500428","article-title":"Mechanisms of body weight reduction and metabolic syndrome alleviation by tea","volume":"60","author":"Yang","year":"2016","journal-title":"Mol Nutr Food Res"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3389\/fphar.2018.01366","article-title":"EGCG reduces obesity and white adipose tissue gain partly through AMPK activation in mice","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"216179","DOI":"10.1016\/j.canlet.2023.216179","article-title":"Glucose transporter 4: insulin response mastermind, glycolysis catalyst and treatment direction for cancer progression","volume":"563","author":"Chang","year":"2023","journal-title":"Cancer Lett"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12944-019-0984-9","article-title":"Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study","volume":"18","author":"Ren","year":"2019","journal-title":"Lipids Health Dis"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"e1003100","DOI":"10.1371\/journal.pmed.1003100","article-title":"Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies","volume":"17","author":"Jarvis","year":"2020","journal-title":"PLoS Med"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12967-023-04047-0","article-title":"Lipid metabolism, BMI and the risk of nonalcoholic fatty liver disease in the general population: evidence from a mediation analysis","volume":"21","author":"Lu","year":"2023","journal-title":"J Transl Med"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"e21228","DOI":"10.1016\/j.heliyon.2023.e21228","article-title":"Effects of green tea catechin on the blood pressure and lipids in overweight and obese population-a meta-analysis","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3945\/ajcn.110.010926","article-title":"Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials","volume":"94","author":"Zheng","year":"2011","journal-title":"Am J Clin Nutr"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11010-018-3324-x","article-title":"Epigallocatechin gallate suppresses hepatic cholesterol synthesis by targeting SREBP-2 through SIRT1\/FOXO1 signaling pathway","volume":"448","author":"Li","year":"2018","journal-title":"Mol Cell Biochem"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3390\/antiox10071076","article-title":"Green tea and epigallocatechin gallate (EGCG) for the management of nonalcoholic fatty liver diseases (NAFLD): insights into the role of oxidative stress and antioxidant mechanism","volume":"10","author":"Tang","year":"2021","journal-title":"Antioxidants"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"7815","DOI":"10.1007\/s11033-023-08666-0","article-title":"Biomarkers of liver diseases","volume":"50","author":"Tamber","year":"2023","journal-title":"Mol Biol Rep"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.canep.2016.01.002","article-title":"Prospective association of liver function biomarkers with development of hepatobiliary cancers","volume":"40","author":"Stepien","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"1700483","DOI":"10.1002\/mnfr.201700483","article-title":"Potential biological effects of (-)-epigallocatechin-3-gallate on the treatment of nonalcoholic fatty liver disease","volume":"62","author":"Chen","year":"2018","journal-title":"Mol Nutr Food Res"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/medicines9030020","article-title":"Salubrious effects of green tea catechins on fatty liver disease: a systematic review","volume":"9","author":"Abunofal","year":"2022","journal-title":"Medicines"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.clnu.2015.05.003","article-title":"Therapeutic effect of high-dose green tea extract on weight reduction: a randomized, double-blind, placebo-controlled clinical trial","volume":"35","author":"Chen","year":"2016","journal-title":"Clin Nutr"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.fitote.2013.07.014","article-title":"Effect of green tea and its polyphenols on mouse liver","volume":"90","author":"Saleh","year":"2013","journal-title":"Fitoterapia"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"476180","DOI":"10.1155\/2015\/476180","article-title":"In vitro toxicity of epigallocatechin gallate in rat liver mitochondria and hepatocytes","volume":"2015","author":"Kucera","year":"2015","journal-title":"Oxid Med Cell Longev"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.3390\/molecules23092346","article-title":"Bioavailability of tea catechins and its improvement","volume":"23","author":"Cai","year":"2018","journal-title":"Molecules"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/advances\/nmaa106","article-title":"A comprehensive systematic review of the effects of naringenin, a citrus-derived flavonoid, on risk factors for nonalcoholic fatty liver disease","volume":"12","author":"Naeini","year":"2021","journal-title":"Adv Nutr"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1111\/bph.14938","article-title":"Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3\/NF-\u03baB pathway in mice","volume":"177","author":"Wang","year":"2020","journal-title":"Br J Pharmacol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"153412","DOI":"10.1016\/j.phymed.2020.153412","article-title":"Naringenin alleviates nonalcoholic steatohepatitis in middle-aged Apoe\u2212\/\u2212 mice: role of SIRT1","volume":"81","author":"Hua","year":"2021","journal-title":"Phytomedicine"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejphar.2016.01.002","article-title":"Apigenin and naringenin regulate glucose and lipid metabolism, and ameliorate vascular dysfunction in type 2 diabetic rats","volume":"773","author":"Ren","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"7826","DOI":"10.1002\/fsn3.3700","article-title":"Naringenin prevents non-alcoholic steatohepatitis by modulating the host metabolome and intestinal microbiome in MCD diet-fed mice","volume":"11","author":"Cao","year":"2023","journal-title":"Food Sci Nutr"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3109\/10717544.2014.923957","article-title":"Safety evaluation of naringenin upon experimental exposure on rat gastrointestinal epithelium for novel optimal drug delivery","volume":"23","author":"Surampalli","year":"2016","journal-title":"Drug Deliv"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.3748\/wjg.v24.i16.1679","article-title":"Beneficial effects of naringenin in liver diseases: molecular mechanisms","volume":"24","author":"Hern\u00e1ndez-Aquino","year":"2018","journal-title":"World J Gastroenterol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.3390\/plants9121784","article-title":"Multi-therapeutic potential of naringenin (4\u2032,5,7-trihydroxyflavonone): experimental evidence and mechanisms","volume":"9","author":"Arafah","year":"2020","journal-title":"Plants"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.lfs.2018.10.066","article-title":"Pharmacokinetic, pharmacodynamic and formulations aspects of naringenin: an update","volume":"215","author":"Joshi","year":"2018","journal-title":"Life Sci"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"931931","DOI":"10.3389\/fphys.2022.931931","article-title":"Low-density lipoprotein particles in atherosclerosis","volume":"13","author":"Qiao","year":"2022","journal-title":"Front Physiol"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"601290","DOI":"10.3389\/fendo.2020.601290","article-title":"FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases","volume":"11","author":"Tillman","year":"2020","journal-title":"Front Endocrinol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"108391","DOI":"10.1016\/j.pharmthera.2023.108391","article-title":"PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: pathogenesis and therapeutic targets","volume":"245","author":"Chen","year":"2023","journal-title":"Pharmacol Ther"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"e0159191","DOI":"10.1371\/journal.pone.0159191","article-title":"Ampelopsin improves insulin resistance by activating PPAR\u03b3 and subsequently up-regulating FGF21-AMPK signaling pathway","volume":"11","author":"Zhou","year":"2016","journal-title":"PLoS One"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.4014\/jmb.2406.06048","article-title":"Dihydromyricetin alleviates non-alcoholic fatty liver disease by modulating gut microbiota and inflammatory signaling pathways","volume":"34","author":"Kang","year":"2024","journal-title":"J Microbiol Biotechnol"},{"key":"ref114","first-page":"622","article-title":"Study on biological efficacy of dihydromyricetin","volume":"29","author":"Xu","year":"2008","journal-title":"Food Science"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"116788","DOI":"10.1016\/j.jep.2023.116788","article-title":"A comprehensive review of vine tea: Origin, research on Materia Medica, phytochemistry and pharmacology","volume":"317","author":"Zeng","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.tifs.2019.07.038","article-title":"Dihydromyricetin: a review on identification and quantification methods, biological activities, chemical stability, metabolism and approaches to enhance its bioavailability","volume":"91","author":"Liu","year":"2019","journal-title":"Trends Food Sci Technol"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/nu8030167","article-title":"Quercetin, inflammation and immunity","volume":"8","author":"Li","year":"2016","journal-title":"Nutrients"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"e22241","DOI":"10.1097\/MD.0000000000022241","article-title":"Quercetin inhibits TNF-\u03b1 induced HUVECs apoptosis and inflammation via downregulating NF-kB and AP-1 signaling pathway in vitro","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201700447","article-title":"Safety aspects of the use of quercetin as a dietary supplement","volume":"62","author":"Andres","year":"2018","journal-title":"Mol Nutr Food Res"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3390\/nu15102250","article-title":"Does the Mediterranean diet have any effect on lipid profile, central obesity and liver enzymes in non-alcoholic fatty liver disease (NAFLD) subjects? A systematic review and meta-analysis of randomized control trials","volume":"15","author":"Del Bo","year":"2023","journal-title":"Nutrients"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.clnu.2022.06.037","article-title":"The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis","volume":"41","author":"Haigh","year":"2022","journal-title":"Clin Nutr"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3390\/nu12041066","article-title":"Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases","volume":"12","author":"Mirabelli","year":"2020","journal-title":"Nutrients"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.3390\/nu13061951","article-title":"Mediterranean diet as an antioxidant: the impact on metabolic health and overall wellbeing","volume":"13","author":"Gantenbein","year":"2021","journal-title":"Nutrients"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26040985","article-title":"Antioxidant and anti-inflammatory potential of polyphenols contained in Mediterranean diet in obesity: molecular mechanisms","volume":"26","author":"Nani","year":"2021","journal-title":"Molecules"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1582861\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T08:34:14Z","timestamp":1746779654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1582861\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":124,"alternative-id":["10.3389\/fnut.2025.1582861"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2025.1582861","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"article-number":"1582861"}}